Latest news and press releases about Monte Rosa Therapeutics, Inc. (GLUE): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers.
Price
| Price | $12.65 |
| Market Cap | $1.1B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.38 |
| EV / EBITDA | -7.17 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -43.31% |
| Return on Invested Capital | -28.19% |
| Return on Assets | -23.15% |
| Gross Margin | 92.94% |
| Operating Margin | -633.04% |
| Net Margin | -560.85% |
Related companies: ARVN · AVBP · DAWN · DNA · GERN · MGTX · REPL
Explore sector: Healthcare · Biotechnology
More sections of GLUE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks